Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.

Koshiro SonomotoShingo NakayamadaYoshihisa FujinoHiroko MiyataSatoshi KuboYuya FujitaYoshino InoueSatsuki MatsunagaShigeru IwataKentaro HanamiYasuyuki TodorokiHiroko Yoshinari-KorekodaAkio KawabeAyako YamaguchiMasanobu UenoYurie Satoh-KandaRyuichiro KandaMasashi FunadaNaoaki OhkuboKatsuhide KusakaShumpei KosakaAtsushi NagayasuShunsuke FukuyoMasao NawataYusuke MiyazakiMikiko TokunagaKenichi TanakaYosuke OkadaYoshiya Tanaka

Published in: Rheumatology (Oxford, England) (2023)

Our study suggested the progression of osteoporosis in RA patients during b/tsDMARDs treatment without anti-OP. BTMs may not reflect BMD change. Regular monitoring of BMD in RA should be considered for early management of osteoporosis.

Keyphrases

bone loss
postmenopausal women
rheumatoid arthritis
end stage renal disease
bone mineral density
ejection fraction
cross sectional
cancer therapy
patient reported outcomes
drug delivery
rheumatoid arthritis patients
replacement therapy